logo

Vertex Pharmaceuticals Inc. (VRTX)



Trade VRTX now with
  Date
  Headline
8/20/2018 3:01:42 AM Vertex Receives PBAC Recommendation For ORKAMBI To Be Listed On Pharmaceutical Benefits Scheme In Australia
8/7/2018 3:55:58 PM Vertex: FDA Approves ORKAMBI As First Medicine To Treat Underlying Cause Of Cystic Fibrosis For Children 2-5 Years
7/27/2018 10:24:11 AM Vertex Gets CHMP Positive Opinion For SYMKEVI For People With Cystic Fibrosis Aged 12& Older With Mutations In CFTR Gene
7/25/2018 4:34:40 PM Vertex Pharmaceuticals Inc. (VRTX) Has Raised Its 2018 Revenue Estimate To $2.90 - $3.00 Bln From $2.65 - $2.80 Bln
7/25/2018 4:02:26 PM Vertex Pharma Q2 EPS $0.80 Vs. $0.07 Year Ago
6/28/2018 11:21:49 AM Canada Oks PrSYMDEKO To Treat Underlying Cause Of CF In People Ages 12 And Older With Certain Mutations In CFTR Gene
6/18/2018 7:03:45 AM Vertex Announces Long-Term Access Agreement In Sweden For Cystic Fibrosis Medicine ORKAMBI
6/12/2018 8:35:05 AM Bioasis Names Mario Saltarelli SVP, Early Development And Neurology, Vertex
6/7/2018 4:39:20 AM Vertex Pharma Says Data From KALYDECO Studies Show Potential To Modify Long-term Progression Of Disease